New Enterprise Associates made
its first biotech investment in Europe last week by leading a €23
million ($29.7 million) third venture round for Prosensa B.V., the Dutch
rare genetic diseases company.
For about 35 years, NEA has
invested almost exclusively in the U.S. for biopharma, with a focus on
hubs like Cambridge, Mass., and northern California.